Cargando…
The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
OBJECTIVE: To investigate the expression and clinical significance of ERCC1 and BRCA1 genes in urothelial cancer patients. METHODS: Forty-two urothelial cancer patients who did not receive platinum-based chemotherapy during January 2009 to May 2013 were enrolled. The expression levels of ERCC1 and B...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913982/ https://www.ncbi.nlm.nih.gov/pubmed/27366083 http://dx.doi.org/10.2147/OTT.S101319 |
_version_ | 1782438491361116160 |
---|---|
author | Song, Wenhui Ma, Hongshun |
author_facet | Song, Wenhui Ma, Hongshun |
author_sort | Song, Wenhui |
collection | PubMed |
description | OBJECTIVE: To investigate the expression and clinical significance of ERCC1 and BRCA1 genes in urothelial cancer patients. METHODS: Forty-two urothelial cancer patients who did not receive platinum-based chemotherapy during January 2009 to May 2013 were enrolled. The expression levels of ERCC1 and BRCA1 were determined by immunohistochemistry and the median survival time (MST) for these patients was calculated. RESULTS: ERCC1-positive patients who received oxaliplatin-based chemotherapy had a shorter MST than ERCC1-negative patients (P<0.05), whereas there is no difference of MST between BRCA1-positive and -negative patients. Furthermore, MST in ERCC1 and BRCA1 double-positive patients was shorter than ERCC1 and BRCA1 double-negative patients (P<0.05). The positive expression of ERCC1 had a significant positive correlation with BRCA1 (r=0.313, P=0.044). CONCLUSION: The expression level of ERCC1 may be used as a prognostic marker for urothelial cancer patients who received postoperative adjuvant chemotherapy. |
format | Online Article Text |
id | pubmed-4913982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-49139822016-06-30 The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer Song, Wenhui Ma, Hongshun Onco Targets Ther Original Research OBJECTIVE: To investigate the expression and clinical significance of ERCC1 and BRCA1 genes in urothelial cancer patients. METHODS: Forty-two urothelial cancer patients who did not receive platinum-based chemotherapy during January 2009 to May 2013 were enrolled. The expression levels of ERCC1 and BRCA1 were determined by immunohistochemistry and the median survival time (MST) for these patients was calculated. RESULTS: ERCC1-positive patients who received oxaliplatin-based chemotherapy had a shorter MST than ERCC1-negative patients (P<0.05), whereas there is no difference of MST between BRCA1-positive and -negative patients. Furthermore, MST in ERCC1 and BRCA1 double-positive patients was shorter than ERCC1 and BRCA1 double-negative patients (P<0.05). The positive expression of ERCC1 had a significant positive correlation with BRCA1 (r=0.313, P=0.044). CONCLUSION: The expression level of ERCC1 may be used as a prognostic marker for urothelial cancer patients who received postoperative adjuvant chemotherapy. Dove Medical Press 2016-06-15 /pmc/articles/PMC4913982/ /pubmed/27366083 http://dx.doi.org/10.2147/OTT.S101319 Text en © 2016 Song and Ma. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Song, Wenhui Ma, Hongshun The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer |
title | The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer |
title_full | The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer |
title_fullStr | The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer |
title_full_unstemmed | The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer |
title_short | The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer |
title_sort | expression of ercc1 and brca1 predicts prognosis of platinum-based chemotherapy in urothelial cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913982/ https://www.ncbi.nlm.nih.gov/pubmed/27366083 http://dx.doi.org/10.2147/OTT.S101319 |
work_keys_str_mv | AT songwenhui theexpressionofercc1andbrca1predictsprognosisofplatinumbasedchemotherapyinurothelialcancer AT mahongshun theexpressionofercc1andbrca1predictsprognosisofplatinumbasedchemotherapyinurothelialcancer AT songwenhui expressionofercc1andbrca1predictsprognosisofplatinumbasedchemotherapyinurothelialcancer AT mahongshun expressionofercc1andbrca1predictsprognosisofplatinumbasedchemotherapyinurothelialcancer |